Finally, the ACR position statement recommended that biosimilars have distinctive names to easily distinguish them from their reference agents. Otherwise, name confusion could lead to prescribing errors and mistakes during surveillance for adverse events, the organization said.
“We will continue to follow the various issues surrounding the distribution, monitoring, and reimbursement of biosimilars very closely as state and federal policies are proposed that affect our patients and the rheumatologists who serve them,” Dr. St.Clair concluded. “Ensuring patients have easy access to affordable treatment options and rheumatology care continues to be a high priority for us.”